Reduced occurrence of early atopic dermatitis because of immunoactive prebiotics among low-atopy-risk infants - 07/08/11
MIPS 1 Working Group
Abstract |
Background |
Most infants developing atopic dermatitis have a low risk for atopy. Primary prevention of atopic dermatitis is difficult.
Objective |
To assess the effect of supplementation of an infant and follow-on formula with prebiotic and immunoactive oligosaccharides on the occurrence of atopic dermatitis in the first year of life.
Methods |
Healthy term infants from 5 European countries with low atopy risk were recruited before the age of 8 weeks, either having started with formula feeding or being on full breast-feeding (breast-feeding group). Formula-fed infants were randomized to feeding with a regular formula containing a specific mixture of neutral oligosaccharides and pectin-derived acidic oligosaccharides (prebiotic formula group) or regular formula without oligosaccharides (control formula group).
Results |
A total of 414 infants were randomized to the prebiotic group and 416 infants to the control group. A total of 300 infants were followed in the breast-feeding group. Up to the first birthday, atopic dermatitis occurred in significantly fewer infants from the prebiotic group (5.7%) than from the control group (9.7%; P = .04). The cumulative incidence of atopic dermatitis in the prebiotic group was in the low range of the breast-feeding group (7.3%). In a Cox regression model, the rate of atopic dermatitis was significantly lower by 44% in the prebiotic group versus the control group (P = .04). The number needed to prevent 1 case of atopic dermatitis by supplementation of prebiotics was 25 infants.
Conclusion |
Formula supplementation with a specific mixture of oligosaccharides was effective as primary prevention of atopic dermatitis in low atopy risk infants.
El texto completo de este artículo está disponible en PDF.Key words : Oligosaccharides, atopic dermatitis, infant, primary prevention, prebiotics
Abbreviations used : AD, BG, CG, lcFOS, pAOS, PG, scGOS, SCORAD, TARC
Esquema
Supported by Danone Research, Friedrichsdorf, Germany. The role of the funder has been to supply the study formulas and facilitate the data collection and data analysis. |
|
Disclosure of potential conflict of interest: C. Grüber receives honoraria from Danone. F. Mosca receives research support from Danone/Numico. C. P. Braegger has consultant arrangements and receives research support from Danone. J. Riedler is on the advisory board for Numico and receives research support from MIPS. U. Wahn receives research support from Danone. The rest of the authors have declared that they have no conflict of interest. |
Vol 126 - N° 4
P. 791-797 - octobre 2010 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?